QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
a partnership with the International Panel Physicians Association
(IPPA) to support and educate panel physicians around the globe on
the latest tuberculosis (TB) screening requirements. A special
focus will be on the new Interferon Gamma Release Assay (IGRA)
requirements and the associated benefits for patients and
healthcare providers.
This collaboration follows the U.S. Centers for
Disease Control and Prevention (CDC) updating its guidelines for
new TB screening requirements for immigrants to the United States.
Together, QIAGEN and IPPA are committed to promoting the use of
IGRA testing, such as QIAGEN’s QuantiFERON-TB Plus, to ensure a
safe immigration process and support the global fight against TB.
IPPA is a U.S.-based non-profit organization of physicians who are
authorized to conduct immigration medical evaluations by
governments of countries that receive migrants, including the U.S.,
Australia, Canada, New Zealand and the United Kingdom.
“Our collaboration with IPPA enables us to raise
awareness about the benefits of IGRA testing and support the U.S.
national strategy to eliminate TB domestically by 2050. This
partnership will lead to better detection of latent TB infection
before departure for the United States and help identify immigrants
who would benefit from preventive treatment,” said Fernando Beils,
Senior Vice President and Head of the Molecular Diagnostics
business area at QIAGEN.
Alexandra Ortega, MPH, MCHES, Executive Director
of the IPPA, said, “Working together with QIAGEN allows us to
educate panel physicians on the latest TB screening requirements,
ensuring patients receive the most accurate and efficient testing
available. This partnership will play a crucial role in global
efforts to combat TB.”
The updated CDC guidelines now mandate that by
October 1, 2024, all individuals aged above 2 years old from
countries with a WHO-estimated TB incidence rate of more than 20
cases per 100,000 people will require an IGRA test as part of their
U.S. immigrant visa medical exam, expanding from the previous
requirement covering only children age 2 to 14.
Additionally, in anticipation of World TB Day,
QIAGEN is hosting a global CPD-accredited event on March 21, 2024,
with top TB experts discussing the vital theme of “TB infection
screening and preventive therapy for achieving End TB strategy
goals”. The program will explore the global TB landscape, advances
in testing and prevention, and screening of migrants. A panel
discussion will address TB epidemiology, cost-effectiveness, and
challenges faced by high-risk groups like migrants and
children.
Tuberculosis is a contagious bacterial infection
spread primarily by coughing of patients with the active pulmonary
form of the disease. The WHO estimated that there were more than 10
million new cases of active TB worldwide and 1.3 million deaths in
2022. One in four people worldwide are believed to have latent TB
infections, with 5-10% of them expected at some point to develop
active TB. Screening for latent TB infection is therefore essential
in the effort to end TB.
QIAGEN’s QuantiFERON-TB Gold Plus assay
accurately detects TB infection by identifying interferon-gamma
released by T-cells in response to TB-specific antigens. This
one-visit test outperforms the century‑old, two-visit TB skin test
(TST), particularly for patients from high-TB-burden countries who
have received BCG vaccination. The CDC and WHO endorse the use of
QuantiFERON-TB Gold Plus to combat the global TB epidemic.
For more information and to register for this
event, please visit
https://www.qiagen.com/us/applications/tb-management/events/world-tb-day
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
December 31, 2023, QIAGEN employed approximately 6,000 people
in over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, timing for launch
and development, marketing and/or regulatory approvals, financial
and operational outlook, growth and expansion, collaborations,
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, and its
impact on the demand for our products and other aspects of our
business, or other force majeure events; as well as the possibility
that expected benefits related to recent or pending acquisitions
may not materialize as expected; and the other factors discussed
under the heading “Risk Factors” contained in Item 3 of our most
recent Annual Report on Form 20-F. For further information, please
refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024